Accelerated Approval Gives Wings To Pandemic Flu Vaccine Development
Executive Summary
FDA has unveiled a strategy for preventing influenza vaccine shortages and getting a jump on flu pandemics by using surrogate endpoints to accelerate approval of new vaccines
You may also be interested in...
Fluad Adjuvant Could Come Under Fire At Advisory Committee
CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.
Final FDA flu vaccine guidances
FDA issues final guidances to outline the regulatory pathways for development and approval of seasonal and pandemic influenza vaccines May 31. Both guidances recommend use of novel adjuvants and cell culture and recombinant manufacturing technologies. Guidelines also allow use of surrogate endpoints such as immune response to support accelerated approval (1"The Pink Sheet" March 13, 2006, p. 26)...
Final FDA flu vaccine guidances
FDA issues final guidances to outline the regulatory pathways for development and approval of seasonal and pandemic influenza vaccines May 31. Both guidances recommend use of novel adjuvants and cell culture and recombinant manufacturing technologies. Guidelines also allow use of surrogate endpoints such as immune response to support accelerated approval (1"The Pink Sheet" March 13, 2006, p. 26)...